Abstract: The present invention provides methods for diagnosis, prognosis, prevention and/or treatment of cancers such as melanomas. The subject invention provides biomarkers and methods for assessing the severity of a cancer/tumor and for monitoring the progressing of a cancer/tumor. The subject invention also provides therapeutic targets in cancer for developing anti-cancer therapies.

Abstract: The present invention provides methods for diagnosis, prognosis, prevention and/or treatment of cancers such as melanomas. The subject invention provides biomarkers and methods for assessing the severity of a cancer/tumor and for monitoring the progressing of a cancer/tumor. The subject invention also provides therapeutic targets in cancer for developing anti-cancer therapies.

Abstract: The subject invention provides novel methods for treating B cell malignancies, such as multiple myeloma, using a combination therapy. Said treatment in accordance with the subject invention comprises the administration of a B cell regulator, e.g., a galectin molecule, to a subject suffering from a B cell malignancy, and wherein said subject received, receives, or will receive a treatment with a conventional treatment for such B cell malignancy, e.g., immunotherapy. The administration of the galectin molecule boosts the expression of B cell specific antigens e.g., SLAMF7, on MM cells, thereby increasing the sensitivity of MM cells to anti-SLAMF7 Ab and therapeutic efficacy of Elotuzumab.

Abstract: The present invention provides methods and composition for diagnosis, prognosis, prevention and/or treatment of cancers such as melanomas. The subject invention provides biomarkers and methods for assessing the severity of a cancer/tumor and for monitoring the progressing of a cancer/tumor. The biomarkers include glycosylation-rerated genes and molecules affected by the glycosylation-rerated genes. The compositions according to the subject invention regulate malignancy-associated pathways and alter melanoma signaling, growth, and survival.

Abstract: Disclosed herein are assays and methods to determine tumor malignancy, for example, in melanoma or ovarian carcinoma, by determining the expression level of Gal-1 ligands. Also provided are methods to assess the metastatic potential of a tumor.

Abstract: Described are Galectin-1/Ig fusion constructs and methods of use thereof, e.g., in diagnostic and biomedical assays, and as therapeutic agents for the treatment of conditions associated with immune dysfunction, e.g., autoimmune diseases, and cancers.

Abstract: Described are Galectin-1/Ig fusion constructs and methods of use thereof, e.g., in diagnostic and biomedical assays, and as therapeutic agents for the treatment of conditions associated with immune dysfunction, e.g., autoimmune diseases, and cancers.

Abstract: Described are Galectin-1/Ig fusion constructs and methods of use thereof, e.g., in diagnostic and biomedical assays, and as therapeutic agents for the treatment of conditions associated with immune dysfunction, e.g., autoimmune diseases, and cancers.

Abstract: The present invention provides compositions and methods for inhibiting cell migration, e.g., lymphocytes and inflammation. The invention also provides an improved process for preparing fluorinated N-acetylglucosamines.

Abstract: The present invention provides compositions and methods for inhibiting cell migration, e.g., lymphocytes and inflammation. The invention also provides an improved process for preparing fluorinated N-acetylglucosamines.